## 1-Methyl-6-methoxy-dihydro-beta-carboline (6-MeO-DHβC)
**What it is:**
1-Methyl-6-methoxy-dihydro-beta-carboline (6-MeO-DHβC) is a naturally occurring alkaloid found in various plants, including *Peganum harmala*, a medicinal plant used in traditional medicine. It is a member of the beta-carboline family, which are known for their psychoactive properties.
**Why it is important for research:**
6-MeO-DHβC has attracted significant research interest due to its potential pharmacological effects and its role in several biological processes. Here are some key reasons:
**1. Potential therapeutic benefits:**
* **Antioxidant and neuroprotective properties:** 6-MeO-DHβC has been shown to possess antioxidant activity, protecting cells against oxidative stress and potentially contributing to neuroprotection.
* **Antidepressant and anxiolytic effects:** Studies suggest that 6-MeO-DHβC might have antidepressant and anxiolytic properties, possibly by modulating neurotransmitter systems in the brain.
* **Anti-inflammatory properties:** 6-MeO-DHβC exhibits anti-inflammatory activity, potentially making it a promising therapeutic agent for inflammatory conditions.
* **Cancer research:** Research is exploring the potential of 6-MeO-DHβC as a cancer treatment, investigating its effects on tumor growth and cell proliferation.
**2. Role in biological processes:**
* **MAO inhibition:** 6-MeO-DHβC is a potent inhibitor of monoamine oxidase (MAO), an enzyme that breaks down neurotransmitters like serotonin, dopamine, and norepinephrine. This inhibition can influence neurotransmitter levels and potentially contribute to its psychoactive effects.
* **Interactions with other receptors:** 6-MeO-DHβC might interact with other receptors in the brain, including serotonin receptors, further contributing to its pharmacological actions.
* **Potential for addiction:** Some studies have linked 6-MeO-DHβC to addictive potential, highlighting the importance of further research into its safety and long-term effects.
**3. Research challenges:**
* **Limited research data:** Despite its potential, research on 6-MeO-DHβC is still relatively limited, requiring further investigation to fully understand its mechanisms of action and potential therapeutic applications.
* **Safety concerns:** Some studies have raised concerns about the safety of 6-MeO-DHβC, including potential for toxicity and addiction. More research is needed to assess its safety profile and establish safe dosages.
**Overall, 6-MeO-DHβC represents a promising compound with potential therapeutic benefits in various areas of medicine. However, further research is essential to fully understand its mechanisms of action, optimize its therapeutic potential, and ensure its safety for human use.**
ID Source | ID |
---|---|
PubMed CID | 417052 |
CHEMBL ID | 338115 |
CHEBI ID | 92962 |
SCHEMBL ID | 3877767 |
MeSH ID | M0130327 |
Synonym |
---|
6-methoxyharmalane |
6-methoxyharmalan |
6-methoxy-1-methyl-4,9-dihydro-3h-pyrido(3,4-b)indole monohydrochloride |
3h-pyrido(3,4-b)indole, 4,9-dihydro-6-methoxy-1-methyl-, monohydrochloride |
1-methyl-6-methoxy-dihydro-beta-carboline |
10-methoxyharmalan |
MLS002153914 |
smr001233263 |
BRD-K54906270-001-03-5 |
PRESTWICK_324 |
methoxy-6-harmalan |
3589-73-9 |
NCGC00016633-01 |
cas-3589-73-9 |
BPBIO1_000642 |
PRESTWICK2_000621 |
PRESTWICK3_000621 |
OPREA1_335320 |
BSPBIO_000582 |
PRESTWICK0_000621 |
SPBIO_002801 |
PRESTWICK1_000621 |
NCGC00016633-02 |
6-methoxyharmalan, crystalline |
bdbm50132104 |
6-methoxy-1-methyl-4,9-dihydro-3h-beta-carboline |
CHEMBL338115 , |
6-methoxy-harmalan |
6-methoxy-1-methyl-3,4-dihydro-2h-pyrido[3,4-b]indole |
HMS1569N04 |
HMS2096N04 |
unii-43f45vjv8c |
43f45vjv8c , |
A823026 |
HMS2233C16 |
FT-0634918 |
1-methyl-6-methoxy-dihydro-.beta.-carboline |
1-methyl-6-methoxy-3,4-dihydro-2-carboline |
10-methoxyharmalan [mi] |
4,9-dihydro-6-methoxy-1-methyl-3h-pyrido(3,4-b)indole |
3,4-dihydromethoxyharman |
HMS3370E16 |
SCHEMBL3877767 |
3h-pyrido(3,4-b)indole, 4,9-dihydro-6-methoxy-1-methyl- |
6-methoxy-1-methyl-3,4-dihydro-.beta.-carboline |
6-methoxy-1-methyl-4,9-dihydro-3h-pyrido(3,4-b)indole |
3h-pyrido(3,4-b)indole, 4,9-dihydro-6-methoxy-1-methyl-, monohydrochloride (salt/mix) |
6-methoxy-1-methyl-4,9-dihydro-3h-pyrido(3,4-b)indole monohydrochloride (salt/mix) |
HMBHRMFLDKKSCT-UHFFFAOYSA-N |
SR-01000841225-2 |
sr-01000841225 |
CHEBI:92962 |
AS-65610 |
Q27164697 |
PIRYBCJVLMHZOK-UHFFFAOYSA-N |
6-methoxy-1-methyl-3h,4h,9h-pyrido[3,4-b]indole |
6-methoxy-1-methyl-4,9-dihydro-3h-pyrido[3,4-b]indole |
Q27258644 |
noname_1047 |
DTXSID10901872 |
DTXSID80957306 |
AKOS037646003 |
ethyl3-(naphthalen-8-yl)-3-oxopropanoate |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 17.7828 | 0.0040 | 23.8416 | 100.0000 | AID485290 |
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 3.5481 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 35.4813 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 12.5893 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
Chain A, ATP-DEPENDENT DNA HELICASE Q1 | Homo sapiens (human) | Potency | 10.0000 | 0.1259 | 19.1169 | 125.8920 | AID2549 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 12.5893 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
15-lipoxygenase, partial | Homo sapiens (human) | Potency | 6.3096 | 0.0126 | 10.6917 | 88.5700 | AID887 |
USP1 protein, partial | Homo sapiens (human) | Potency | 14.1254 | 0.0316 | 37.5844 | 354.8130 | AID504865 |
TDP1 protein | Homo sapiens (human) | Potency | 0.4109 | 0.0008 | 11.3822 | 44.6684 | AID686978 |
bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 44.6684 | 0.7079 | 36.9043 | 89.1251 | AID504333 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 18.5482 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 0.6310 | 0.0020 | 7.5337 | 39.8107 | AID891 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 14.5810 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
flap endonuclease 1 | Homo sapiens (human) | Potency | 50.1187 | 0.1337 | 25.4129 | 89.1251 | AID588795 |
snurportin-1 | Homo sapiens (human) | Potency | 56.2341 | 5.8048 | 36.1306 | 65.1308 | AID540263 |
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 44.6684 | 0.4256 | 12.0591 | 28.1838 | AID504891 |
geminin | Homo sapiens (human) | Potency | 8.9125 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 5.0119 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
caspase-1 isoform alpha precursor | Homo sapiens (human) | Potency | 15.8489 | 0.0003 | 11.4484 | 31.6228 | AID900 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 5.0119 | 1.0000 | 12.2248 | 31.6228 | AID885 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
5-hydroxytryptamine receptor 3E | Homo sapiens (human) | Ki | 10.0000 | 0.0010 | 0.8835 | 9.9000 | AID5996 |
Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
5-hydroxytryptamine receptor 3B | Homo sapiens (human) | Ki | 10.0000 | 0.0010 | 0.8711 | 9.9000 | AID5996 |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | IC50 (µMol) | 4.0000 | 0.0003 | 2.1774 | 10.0000 | AID1725119 |
Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.6902 | 10.0000 | AID142899 |
Muscarinic acetylcholine receptor M4 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.7951 | 9.1201 | AID142899 |
5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 10.0000 | 0.0001 | 0.5326 | 10.0000 | AID3824 |
Muscarinic acetylcholine receptor M5 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.7292 | 6.9183 | AID142899 |
Muscarinic acetylcholine receptor M1 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.5972 | 9.1201 | AID142899 |
D(2) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.6518 | 10.0000 | AID63034 |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | Ki | 5.6000 | 0.0001 | 0.6017 | 10.0000 | AID5536 |
Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.5614 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6352 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6217 | 10.0000 | AID39935 |
Muscarinic acetylcholine receptor M3 | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.5405 | 7.7600 | AID142899 |
D(1A) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0001 | 0.8363 | 10.0000 | AID63034 |
D(4) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.4362 | 10.0000 | AID63034 |
D(1B) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0003 | 0.4017 | 7.9000 | AID63034 |
Metabotropic glutamate receptor 1 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0079 | 0.3145 | 0.9000 | AID108345 |
Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6758 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6469 | 10.0000 | AID39935 |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | Ki | 4.1000 | 0.0003 | 1.4656 | 10.0000 | AID145367 |
5-hydroxytryptamine receptor 1D | Homo sapiens (human) | Ki | 10.0000 | 0.0001 | 0.8087 | 10.0000 | AID4616 |
5-hydroxytryptamine receptor 1B | Homo sapiens (human) | Ki | 10.0000 | 0.0001 | 0.5485 | 9.2100 | AID4247 |
5-hydroxytryptamine receptor 2C | Homo sapiens (human) | Ki | 0.9240 | 0.0001 | 0.9549 | 10.0000 | AID5615 |
Neuromedin-B receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0002 | 0.0008 | 0.0020 | AID4247 |
Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6712 | 10.0000 | AID39935 |
Metabotropic glutamate receptor 2 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0031 | 0.1265 | 0.4760 | AID108345 |
Metabotropic glutamate receptor 3 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0030 | 0.1340 | 0.4760 | AID108345 |
Metabotropic glutamate receptor 4 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.1600 | 1.7800 | 3.4000 | AID108345 |
Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0005 | 0.1964 | 3.7600 | AID108345 |
Sodium-dependent serotonin transporter | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.7048 | 8.1930 | AID204092 |
5-hydroxytryptamine receptor 7 | Homo sapiens (human) | Ki | 2.9600 | 0.0003 | 0.3806 | 10.0000 | AID6591 |
Metabotropic glutamate receptor 7 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.1100 | 0.1100 | 0.1100 | AID108345 |
D(3) dopamine receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.6020 | 10.0000 | AID63034 |
5-hydroxytryptamine receptor 3A | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.7411 | 9.9000 | AID5996 |
5-hydroxytryptamine receptor 5A | Homo sapiens (human) | Ki | 10.0000 | 0.0008 | 0.9433 | 5.1600 | AID6482; AID6500 |
5-hydroxytryptamine receptor 6 | Homo sapiens (human) | Ki | 1.9300 | 0.0002 | 0.5229 | 10.0000 | AID6517 |
Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.5577 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6403 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.5708 | 10.0000 | AID39935 |
Metabotropic glutamate receptor 8 | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 1.9000 | 2.6500 | 3.4000 | AID108345 |
Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | IC50 (µMol) | 2.0000 | 0.0005 | 0.4008 | 6.2000 | AID1725120; AID1725121; AID1725122 |
5-hydroxytryptamine receptor 3D | Homo sapiens (human) | Ki | 10.0000 | 0.0010 | 0.8835 | 9.9000 | AID5996 |
5-hydroxytryptamine receptor 3C | Homo sapiens (human) | Ki | 10.0000 | 0.0010 | 0.8835 | 9.9000 | AID5996 |
GABA theta subunit | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Ki | 10.0000 | 0.0002 | 0.6561 | 10.0000 | AID39935 |
Transporter | Rattus norvegicus (Norway rat) | Ki | 4.1000 | 0.0001 | 0.8667 | 10.0000 | AID145367 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1725122 | Inhibition of mouse COX2 using 2-arachidonylglycerol as substrate preincubated for 3 mins followed by substrate addition and measured for 30 sec by LC/MS analysis | 2020 | ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10 | Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. |
AID1725120 | Inhibition of mouse COX2 using [1-14C]AA as substrate preincubated for 20 mins followed by substrate addition and measured for 30 sec by thin layer chromatography analysis | 2020 | ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10 | Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. |
AID333916 | Genotoxicity in CHO cells assessed as chromosomal aberrations at 10 ppm after 90 mins in dark | |||
AID333915 | Genotoxicity in CHO cells assessed as chromosomal aberrations at 10 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID1725119 | Inhibition of ovine COX1 using [1-14C]AA as substrate preincubated for 20 mins followed by substrate addition and measured for 30 sec by thin layer chromatography analysis | 2020 | ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10 | Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. |
AID6517 | Binding affinity towards human 5-hydroxytryptamine 6 receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID204092 | Binding affinity towards Serotonin transporter | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID63034 | Binding affinity towards Dopamine receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID142899 | Binding affinity towards Muscarinic acetylcholine receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333921 | Genotoxicity in CHO cells assessed as chromosomal aberrations at 1.25 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID39935 | Binding affinity towards GABA-A benzodiazepine receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID223228 | Binding affinity towards Imidazoline I1 receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333906 | Genotoxicity in CHO cells assessed as chromosomal aberrations at 2.5 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID36401 | Binding affinity towards Alpha-2C adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID108345 | Binding affinity towards Glutamate (rPCP) receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333949 | Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.07 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID6591 | Binding affinity towards 5-hydroxytryptamine 7 receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID145367 | Binding affinity towards NET | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333923 | Genotoxicity in CHO cells assessed as mitotic inhibition at 0.31 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID6500 | Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand | 2003 | Journal of medicinal chemistry, Aug-28, Volume: 46, Issue:18 | Binding of tetrahydrocarboline derivatives at human 5-HT5A receptors. |
AID6482 | Binding affinity towards 5-HT5A receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333920 | Genotoxicity in CHO cells assessed as chromosomal aberrations at 0.15 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID1725121 | Inhibition of mouse COX2 using arachidonic acid as substrate preincubated for 3 mins followed by substrate addition and measured for 30 sec by LC/MS analysis | 2020 | ACS medicinal chemistry letters, Oct-08, Volume: 11, Issue:10 | Harmaline Analogs as Substrate-Selective Cyclooxygenase-2 Inhibitors. |
AID4247 | Binding affinity towards 5-hydroxytryptamine 1B receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID36595 | Binding affinity towards Alpha-1A adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID35940 | Binding affinity towards Alpha-2A adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID5536 | Binding affinity towards 5-hydroxytryptamine 2A receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333918 | Genotoxicity in CHO cells assessed as mitotic inhibition at 0.62 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID4616 | Binding affinity towards 5-hydroxytryptamine 1D receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID36223 | Binding affinity towards Alpha-2B adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID333904 | Genotoxicity in CHO cells assessed as mitotic inhibition at 5 ppm after 60 mins in dark followed by 5 W/m'2 UV irradiation for 30 mins | |||
AID64344 | Binding affinity towards DAT (bovine) | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID5996 | Binding affinity towards 5-HT3 receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID41508 | Binding affinity towards Beta-2A adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID3824 | Binding affinity towards 5-hydroxytryptamine 1A receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID40568 | Binding affinity towards Beta-1A adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID37208 | Binding affinity towards Alpha-1B adrenergic receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID223243 | Binding affinity towards Imidazoline I2 receptor; ND=Not determined | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID5615 | Binding affinity towards 5-hydroxytryptamine 2C receptor | 2003 | Bioorganic & medicinal chemistry letters, Dec-15, Volume: 13, Issue:24 | Binding of beta-carbolines at 5-HT(2) serotonin receptors. |
AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (8.33) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (25.00) | 29.6817 |
2010's | 6 (50.00) | 24.3611 |
2020's | 2 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.49) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 13 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |